Randomized trial compares treatment effects using hazard ratio and restricted mean survival time in oncology, suggesting RMST should be reported regularly.
On average, the HR provided significantly larger treatment effect estimates than the ratio of RMST. The HR may seem large when the absolute effect is small. RMST-based measures should be routinely reported in randomized trials with time-to-event outcomes.
No takes yet. Share an insight, caveat, or question.
Trinquart et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: